利妥昔单抗注射液联合GDP化疗方案对非霍奇金淋巴瘤患者疗效及免疫功能的影响

Abstract
Figure/Table
References (25)
Related Citation (13)

Download: PDF (501 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma (NHL). Methods Ninety-three NHL patients admitted to Taikang Xianlin Drum Tower Hospital of Nanjing City in Jiangsu Province from May 2014 to December 2017 were selected as the research subjects. The patients were divided into control group (n = 46) and study group (n = 47) according to the random number table method. The control group was treated with the GDP chemotherapy regimen, and the study group was treated with Rituximab Injection on this basis. The clinical efficacy after treatment, immune function indexes [immunoglobulin (Ig) A, IgM, IgG and the body fluid complement C3, C4], tumor markers [thymine deoxy kinase (TK-1), vascular endothelial growth factor (VEGF)] before and after treatment were compared in the two groups. The adverse reactions of the two groups during treatment were observed. Results After treatment, the total effective rate of the study group was significantly higher than the control group (P ＜ 0.05). IgA, IgM, IgG, C3, C4 of the two groups after treatment were lower than those before treatment, C3 and C4 of the study group were lower than those of the control group, the differences were statistically significant (P ＜ 0.05); there was no significant difference in IgA, IgM, IgG between the two groups after treatment (P ＞ 0.05). After treatment, TK-1 and VEGF of the two groups were lower than those before treatment, which of the study group were lower than those of the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P ＞ 0.05). Conclusion Rituximab Injection combined with GDP chemotherapy in the treatment of NHL has a certain effect and can effectively protect the immune functions of the patients, significantly decrease the levels of serum TK-1 and VEGF, and does not increase the incidence of adverse reactions. It has certain clinical application value.

Key words： Rituximab GDP chemotherapy Non Hodgkin lymphoma Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHENG Weiwei1 SHAO Yu2▲

Cite this article:

SHENG Weiwei1 SHAO Yu2▲. Effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma[J]. 中国医药导报, 2018, 15(35): 98-101.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I35/98

[1] 张燕萍，周晓慧，张丽，等.利妥昔单抗联合改良CHOP方案治疗非霍奇金淋巴瘤的临床疗效及安全性评价[J].中国临床药理学杂志，2015，31（12）：1109-1111.
[2] Arroyave-Ospina JC，Caicedo MF，Navas MC，et al. Human Pegivirus：Pathogenic potential and non-Hodgkin lymphoma development risk [J]. Rev Chilena Infectol，2018， 35（2）：164-175.
[3] 李佳，张嵘，胡荣，等.ESHAP方案治疗复发、难治性非霍奇金淋巴瘤疗效观察[J].山东医药，2015，55（15）：44-45.
[4] 汪笑秋，方炳木，江锦红，等.沙利度胺联合CHOP方案治疗侵袭性非霍奇金淋巴瘤的临床疗效及安全性评价[J].中国临床药理学杂志，2015，31（16）：1588-1590.
[5] 燕玮，何晓薇，石雪，等.雷那度胺联合GDP方案治疗老年复发难治性T细胞性非霍奇金淋巴瘤的临床疗效[J].现代肿瘤医学，2016，24（20）：3284-3287.
[6] Ross NA，Vega ML，Keller MS. Rituximab-Treated Pemphigus Foliaceus in a Schizophrenic Patient：A Challenging Exercise in Diagnosis，Management，and Follow-Up [J]. Skinmed，2018，16（2）：129-131.
[7] 王浩，张晓波，刘锋，等.GDP方案治疗复发和难治性非霍奇金淋巴瘤的疗效观察[J].实用癌症杂志，2016，31（4）：668-669，673.
[8] 刘扬帆.不同二线补救化疗方案治疗高龄复发难治性弥漫大B细胞淋巴瘤临床对比研究[J].中国实验血液学杂志，2016，24（2）：448-451.
[9] McDonald JT，Kritharis A，Beheshti A，et al. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel [J]. Oncotarget，2018，9（32）：22693-22702.
[10] 袁文志，梁勇，潘晓芳，等.培门冬酶联合吉西他滨、顺铂和地塞米松方案治疗NK/T细胞淋巴瘤的疗效及安全性[J].癌症进展，2016，14（10）：1007-1009.
[11] 徐立业，刘增辉，李薇，等.CCL22、IL-10和FOXP3在B细胞非霍奇金淋巴瘤组织中的表达及意义[J].山东医药，2015，55（14）：59-61.
[12] Lulla PD，Hill LC，Ramos CA，et al. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma [J]. Clin Adv Hematol Oncol，2018，16（5）：375-386.
[13] 王浩，刘锋，刘秋艳，等.GDP节拍方案对老年复发性及难治性非霍奇金淋巴瘤的临床效果分析[J].中华老年多器官疾病杂志，2015，14（11）：822-824.
[14] 凡治国.利妥昔单抗联合GDP方案治疗非霍奇金淋巴瘤的疗效及对患者免疫水平的影响[J].实用癌症杂志，2018，33（4）：658-660.
[15] Shpilberg O，Jackisch C. Subcutaneous administration of rituximab（MabThera）and trastuzumab（Herceptin）using hyaluronidase [J]. Br J Cancer，2013，109（6）：1556-1561.
[16] Mueller C，Dietel E，Heynen SR，et al. Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under in-use Conditions with Different Administration Materials [J]. Int J Pharm Compd，2015， 19（3）：261-267.
[17] 诸慧，李佩涵，金剑.利妥昔单抗联合CHOP方案治疗中国人群弥漫大B细胞淋巴瘤效果及安全性的Meta分析[J].中国医药导报，2017，14（27）：144-152.
[18] 陈杏梅，覃艳琼，万里鹏.利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效分析[J].癌症进展，2016，14（5）：486-488，491.
[19] 姬卫国，张明智，王祥麒，等.利妥昔单抗注射液对CD20阳性淋巴瘤患者血清血管内皮生长因子和乳酸脱氢酶水平的影响及疗效[J].中国老年学杂志，2012，32（19）：4155-4156.
[20] 卿晓玲，陈自敏，陈瑜，等.肿瘤坏死因子相关凋亡诱导配体在B淋巴瘤细胞株中的敏感性及诱导细胞凋亡机制[J].成都医学院学报，2016，11（4）：413-416，442.
[21] 景莉.利妥昔单抗注射液联合化疗治疗B细胞非霍奇金淋巴瘤疗效观察[J].四川医学，2016，38（8）：916-919.
[22] 李慧娉，祁真，高大.Ⅰ期和Ⅱ期弥漫大B细胞淋巴瘤化疗后完全缓解患者接受放射治疗的效果及影响因素分析[J].中国医学装备，2016，13（10）：68-71.
[23] 沈磊，张伊莉，卞建军，等.利妥昔单抗配合CHOP化疗对非霍奇金淋巴瘤患者血清TK-1、VEGF的影响[J].国际检验医学杂志，2018，39（5）：602-605.
[24] Zhang Y，Wang CP，Ding XX，et al. FNC，a novel nucleoside analogue，blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt/β-catenin signaling pathway [J]. Asian Pac J Cancer Prev，2014，15（16）：6829-6835.
[25] 彭晔，张旭刚，谢娜，等.利妥昔单抗注射液治疗慢性淋巴细胞白血病致过敏性休克1例[J].医药导报，2014， 33（10）：1325-1326.